|Publication number||USRE31006 E|
|Application number||US 05/882,821|
|Publication date||Aug 3, 1982|
|Filing date||Mar 2, 1978|
|Priority date||Sep 24, 1968|
|Publication number||05882821, 882821, US RE31006 E, US RE31006E, US-E-RE31006, USRE31006 E, USRE31006E|
|Inventors||Antonius H. W. M. Schuurs, Bauke K. Van Weemen|
|Original Assignee||Akzona Incorporated|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (58), Non-Patent Citations (188), Referenced by (68), Classifications (22)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a continuation-in-part of application Ser. No. 762,120, filed Sept. 24, 1968, now U.S. Pat. 3,654,090, issued Apr. 4, 1972. .Baddend.
For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances. Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specifically. As examples of such combinations are mentioned cortisol and transcortin, 17β-oestradiol and the oestradiol-binding receptor protein of the uterus.
It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a so-called hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.
High molecular substances, such as simple and conjugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.
Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be determined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature, depend upon the nature of the specific binding protein. They speak of "competitive protein binding assays," where receptor or transport proteins are used, and of "radioimmunological determinations" where antibodies are employed as specific binding protein.
Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance. Where use is made of the binding affinity between a low molecular substance and its specific binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventional in radioimmunological methods.
For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances participating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.
In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low concentrations in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containing antisubstances with an extremely high binding affinity for ACTH.
Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.
Although, in principle, the .[..[.immunoligical.]..]. .Badd.immunological .Baddend.cross-reaction between HCG and LH enables both hormones to be determined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems are insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium. These methods, however, are very laborious, and the results often unsatisfactory.
A process has now been found for the demonstration and determination of a component of the reaction between specific binding proteins and the substances that can be specifically bound by these proteins, using the known binding affinity of such components for each other, which comprises reacting the component to be determined with its binding partner, which has been or is insolubilised, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a coupling product obtained by binding a substance capable of reacting specifically with one of the reaction .[..[.componets.]..]. .Badd.components.Baddend., to an enzyme, and finally determining the enzyme activity of the liquid or the solid phase in the reaction mixture obtained, which is a measure for the quantity of the substance to be determined.
The binding partner required for the determination of the component present in an unknown quantity, is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an insoluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding antisubstances against it.
The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.
The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten/antibody and a low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an antibody against the gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.
The essence of the method is the performance in two steps, in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.
The most important advantages of the method found are:
1. The first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods.
2. In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Expecially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.
The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of blood-clotting fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibodies can be determined in this manner.
The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH .[..[.requied.]..]. .Badd.required .Baddend.for the immunochemical reaction, viz. between 5 and 9, by adding a dry buffer salt or a small volume of a concentrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction. For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.
The manufacture of the insolubilised reaction component can take place in various manners, i.a. dependent upon the properties of this reaction component. Thus, antibodies, specific binding proteins and protein-like antigen can be insolubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative protein coupled with an insoluble carrier. Low molecular substances can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.
The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be .[..[.introduce.]..]. .Badd.introduced .Baddend.by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.
The choice of the enzyme that is to form a part of the coupling product, is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.
According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automated.
In the manufacture of the coupling products enzymes such as catalase, peroxidase, β-glucuronidase, β-B-glucosidase, β-D-galactosidase, urease, .[..[.glucoseoxidase.]..]. .Badd.glucose-oxidase .Baddend.and galactose-oxidase are preferred, especially the group of the oxidoreductases.
The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be determined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors. In order to enable the reaction to be performed in the heterogeneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centrifugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged. Separation by filtration and decantation is also possible.
The second part of the determination is performed by resuspending the insoluble substance, which forms the solid phase, preferably in a buffer, and to react it with a certain quantity of a coupling product of the substance to be determined with an enzyme, for example, peroxidase. After a certain time the solid phase is separated again, for example by centrifugation, after which the enzyme activity in the liquid phase is determined. This enzyme activity is a measure for the quantity of substance to be determined in the test liquid. The second part of the determination can also be performed by reacting the insoluble substance from the first part of the determination, with a coupling product obtained by binding a third substance capable of reacting specifically with the reaction component to be determined, with an enzyme. This will be the case when an antibody is determined by the insolubilised corresponding antigen in the first part of the determination, and a second antibody, against the first, which is coupled with an enzyme, is used in the second part of the determination.
The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a substrate and other substances required for the relative enzyme reaction.
Preferably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.
The form in which the reagents can be used are manifold. The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.
The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.
For the performance of the process according to the invention a test-pack is usually employed, chiefly consisting of:
a. a certain quantity of the enzyme coupling product;
b. a corresponding quantity of one of the components of the reaction system in an insoluble form;
c. a substrate for the determination of the quantity of the enzyme employed.
The test-pack can contain the necessary auxiliaries, if required, to make a dilution series of the sample to be tested for a quantitative determination, such as test tubes, pipettes and flasks containing a diluent, For the determination of antigens or haptens, or their antibodies, the test-pack contains at least:
a. a certain quantity of the coupling product of the antigen or hapten, or an antibody against it, and an enzyme;
b. a corresponding quantity of an insolubilised component of the reaction system antigen/antibody, or hapten/antibody, and
c. a substrate for the determination of the enzyme activity.
The invention is further illustrated by the following examples, which are on no account intended to limit the invention.
Determination of human chorionic gonadotrophin (HCG) in serum.
a. Preparation of HCG-HRP. Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.2. After 40 μ/ltr of 25 percent glutaric aldehyde solution had been added, the mixture was shaken at room temperature for 2 hours. Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.2. The fractions whose highest percentage of .[..[.enqyme.]..]. .Badd.enzyme .Baddend.activity was bound by antibodies against HCG, were used in the test system.
b. Preparation of antibodies against HCG. Antibodies against HCG were generated in rabbits as described by Schuurs et al. in Acta Endocr. (Kbh.) 59, 120 (1968).
c. Preparation of the immuno-adsorbent, anti-HCG-cellulose. The γ-globulin fraction of the anti-HCG-serum described under (b) was prepared by precipitation with 18 percent (w/v) solid Na2 SO4. The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml. M-aminobenzyloxy methyl cellulose (350 mg) prepared by Gurvich's method, described in Biokhimiya 26, 934 (1961), was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36 .[..[.percenthydrochloric.]..]. .Badd.percent hydrochloric .Baddend.acid and, dropwise, 10 ml of 10 percent NaNO2 -solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6 .Badd.of the .Baddend.γ-globulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4° C. centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH 6.0.
d. Determination of HCG in serum. A dilution series of HCG (8--4--2--1--0.5--0.25--0 I.U./ml) was prepared with a dilution liquid consisting of one part of man's serum and 2 part of 0.05 M phosphate buffer of pH 6.2. Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immunoadsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH 6.2, and rotated again at room temperature for 2 hours.
After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of 10 μl of 30% H2 O2 and 20 mg of 5-amino salicylic acid in 150 ml of 0.02 M phosphate buffer of pH 6.0. After 30 minutes the extinction was measured at 460 nm.
In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of 1 I.U./ml caused the maximum increase. In this test the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enzyme activity, i.e. owing to turbidity of the serum and the peroxidase-like activity of it.
The HCG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.
Determination of HCG in low concentrations by means of an enzyme/antigen coupling product.
a. Preparation of antisubstances against rabbit-γ-globulin. Rabbit-γ-globulin was isolated from normal rabbit serum by precipitating it with 18 percent (w/v) solid Na2 SO4. Antibodies against it were generated in a sheep. The injection scheme was:
______________________________________Day Quantity Freund's adjuvant Manner of injection______________________________________ 0 0.5 mg + Intramuscularly14 0.5 mg + "28 1 mg + "42 1 mg - Intravenously56 1 mg - "______________________________________
On day 70 the sheep was exsanguinated.
b. Preparation of [sheep-anti-(rabbit-γ-globulin)] cellulose. The γ-globulin fraction of the sheep serum described under (a) was prepared by precipitating it with 16 percent (w/v) solid sodium sulphate. This γ-globulin fraction was bound to m-aminobenzyloxymethyl-cellulose, as described in example I(c).
c. Determination of .[..[.hyman.]..]. .Badd.human .Baddend.chorionic gonadotrophin (HCG). A dilution series of HCG was prepared in 0.01 M phosphate buffer of pH 6.0, which also contained 2 percent (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./l, the dilution factor being 2.
To 5 ml of a HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see example Ib), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature for 30 minutes, after which 1.5 mg. of [sheep-anti(rabbit-γ-globulin)] cellulose were added and the mixture was rotated for 2 hours.
The cellulose was centrifuged for 10 minutes at 3,000 r.p.m. and resuspended in 1 ml of a solution of HCG-HRP coupling product, prepared in accordance with example I(a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2 percent normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of enzyme substrate consisting of 10 μl of 30 percent H2 O2 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of pH 6.0. The mixture was left to stand for 30 minutes at 25°, after which the extinction was measured at 460 nm. In the supernatant liquid 100 percent enzyme activity is measured provided that no anti-HCG serum is added to the system.
A dilution series of HCG, prepared with children's urine as dilution liquid, gave an identical pattern so that also measurings in the urine samples can be performed.
The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.
Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.
a. Preparation of the immuno-adsorbent HCG cellulose. This immuno-adsorbent was prepared by the method mentioned in example I(c), but instead of rabbit-γ-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.
b. Purification of antibodies against HCG. Ten ml of .[..[.rattib-anti-HCG.]..]. .Badd.rabbit-anti-HCG .Baddend.serum, prepared in accordance with example I(b), was diluted with 90 ml of 0.05 M citrate of pH 5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex G-25. The immuno-adsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2.0. The fractions were collected in one half volume of 0.25 M NaHCO3, tested for their content of antibodies and protein, and the suitable fractions were frozen
c. Preparation of the coupling product (anti-HCG)-HRP. Twenty mg of horse radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 μl of 25 percent glutaric aldehyde solution, after which the mixture was shaken for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.
d. Determination of HCG and LH. Ten ml of a HCG dilution series of HCG and 10 ml of a HCG dilution series of LH were mixed with 5 mg of anti-HCG cellulose, prepared in accordance with example I(c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures .[..[.rotate.]..]. .Badd.rotated .Baddend.at room temperature for 2 hours. The immuno-adsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0.
To the immuno-adsorbent 1 ml of the (anti-HCG)-HRP coupling product was added in the desired dilution, after which the mixture was .[..[.rrotated.]..]. .Badd.rotated .Baddend.again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.
By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per liter respectively could be determined. If the centrifugation step is omitted the optimum sample size is 0.5 .[..[.nl.]..]. .Badd.Ml .Baddend.and the sensitivity about 100 I.U. of HCG per liter of about 200 I.U. of LH per liter, so that the method according to the invention yields a 10-20 fold increase in sensitivity.
Determination of HCG and anti-HCG.
a. Rabbit-serum was fractionated over DEAE cellulose in accordance with the prescription of H. A. Sober and others in J. Am. Chem. Soc. 78, 756 (1956). The isolated γ-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating antibodies in a sheep in accordance with the scheme of example II(a), while besides 100 mg of rabbit-γ-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in example I(c). From the sheep .[..[.[anti-(rabbit-γ-γ-globulin)].]..]. [anti-(rabbit-γ-globulin)] serum prepared the specific antibodies were isolated by the method described in example II(b) with the immmuno-adsorbent III
b. The coupling product [anti-(rabbit-γ-globulin)]-HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in example III(c).
c. Determination of anti-HCG. A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6.0. Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see example IIIa). The reaction mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b. The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in example I(d).
d. Determination of HCG. With the reagents prepared, HCG was determined by incubating solutions of it with 0.5 ml of rabbit-(anti-HCG)-serum in a dilution which in the system described under (c) just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under (c) with the mixture obtained. Where use was made of 5 ml of HCG solution, it proved to be possible to demonstrate concentrations of about 10 I.U./l of HCG.
Determination of insulin in serum.
a. Preparation of insulin-(glucose-oxidase). Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5. To this solution 5 .[..[.γ.]..]. .Badd.μl .Baddend.of 25 percent glutaraldehyde solution was added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity could be bound by antibodies against insulin were used in the test system.
b. Preparation of antibodies against insulin. Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freund's adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.
c. Preparation of anti-substances against cavia γ-globulin. Cavia γ-globulin was prepared by adding one volume of saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33 percent saturated (NH4)2 SO4 solution and then taken up in a physiological salt solution. A sheep was immunized with increasing dosages of the γ-globulin prepared, viz. 0, 5, 1 and 2 mg. The injections were given every 2 weeks, the immunogen being mixed with complete Freund's adjuvant. Two weeks after the last injection another 2 mg of γ-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.
d. Preparation of insoluble antibodies against cavia γ-globulin. Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5 percent (w/v) CNBr-solution, after which the pH was adjusted to 10.5 with an 1 N NaOH-solution, and it was maintained at it for 2 minutes. The cellulose was washed with ice water and with 0.1 M NaHCO3. To 10 ml of sheep-anti-(cavia γ-globulin) serum 1.6 gm of NaSO4 were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16 percent (w/v) Na2 SO4 solution, and finally taken up in 10 ml of 0.1 M NaHCO3.
The activated cellulose was mixed with 40 ml of a 0.1 M NaHCO3 solution and the 10 ml of γ-globulin solution. This suspension was rotated for 40 hours at 4° C. and washed, twice with 5 ml of 0.5 M NaHCO3, twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH 6.2.
c. Determination of insulin in serum. Four ml of an insulin dilution series in the range of from 0-100 ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml of anti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immuno-adsorbent prepared under (d), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4° C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2 percent sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immuno-adsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained 50 mg of glucose, 10 μgm of peroxidase and 1 mg of 5-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6.0.
The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a 10-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.
Determination of oestradiol.
a. Preparation of oestradiol-17-succinyl-HRP. Fifty mg of oestradiol-17-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of dioxane. To the cold solution (2° C.) 15 μl of isobutylchlorocarbonate were added. After 30 minutes this solution was mixed with 100 mg of horse radish peroxidase (HRP) in 7.5 ml of mixture of .Badd.a .Baddend.dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2° C., after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by precipitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.
b. Preparation of oestradiol-17-succinyl-BSA. The preparation was prepared by the mixed anhydride method as described under (a). The starting material was 100 mg of oestradiol-17-haemisuccinate and 150 mg of bovine serum albumin (BSA).
c. Preparation of anti-substances against oestradiol. A sheep was injected every 4 weeks with 4 mg of oestradiol-17-succinyl-BSA in complete Freund's adjuvant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA
Preparation of anti-substances against sheep γ-globulin. Sheep-γ-globulin was prepared as described in example II(b), this time, however, with 16 percent w/v sodium sulphate. Rabbits were immunized with this sheep-γ-globulin in accordance with the following scheme:
______________________________________Day Quantity Freund's adjuvant Manner of injection______________________________________ 0 200 μgm + Intramuscularly14 400 μgm + "28 800 μgm + "42 800 μgm - Intravenously______________________________________
Two weeks after the last injection the animals were exsanguinated.
e. Preparation of the immuno-adsorbent [rabbit-anti(-sheep-γ-globulin)] cellulose.
The γ-globulin fraction of the anti-sera described under (b) was prepared by precipitation with 18 percent w/v Na2 SO4. The product obtained was coupled with cellulose by Gurvich's method described in example I(c).
f. Determination of oestradiol. A dilution series of oestradiol (0--0.5--1--2--4--8--16 ng/ml) was prepared in phosphate buffer of pH 6.0. Five ml of sample were mixed with 0.5 ml of the .[..[.sheep-antio-estradiol-serum.]..]. .Badd.sheep-anti-o-estradiol-serum .Baddend.in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immuno-adsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0 containing 2 percent BSA. Then 1 ml of oestradiol-17-succinyl-HRP, diluted to the desired strength with the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrifuged again and the enzyme activity in the supernatant liquid was measured as described in example I. By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10 .[..[.coompared.]..]. .Badd.compared .Baddend.with the test without centrifugation step.
Determination of cortisol.
a. Preparation of cortisol-21-galactose-oxidase.
Fifty mg of cortisol-21-haemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride method as described in example VI(a).
b. Preparation of insoluble transcortine. One hundred mg of transcortine purified by DEAE cellulose chromatography, followed by hydroxylapatite chromatography, were coupled with 3 gm of Sepharose 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml of 2.5 percent (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose was washed with ice-water and with 0.1 M NaHCO3, after which 100 mg of transcortine in 20 ml .[..[.og.]..]. .Badd.of .Baddend.0.1 M NaHCO3 were added, and the suspension was shaken at 4° C. for 24 hours. After being washed successively with 0.5 M NaHCO3, 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer, to which 0.1 percent merthiolate had been added.
c. Determination of cortisol. A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6.0. .[..[.File.]..]. .Badd.Five .Baddend.ml of each cortisol solution (in 0.5 M phosphate buffer of pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose, at 4° C. After centrifugation 1 ml of cortisol-21-galactose oxidase solution, diluted to a suitable concentration in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4° C. After recentrifugation the enzyme activity in the supernatant liquid was determined by adding 0.5 ml of it to 1.5 ml of substrate consisting of 100 mg of D-galactose, 20 mg of 5-amino-salicylic acid and 10 μgm of peroxidase in 150 ml of 0.02 M phosphate buffer of pH 6.0. Finally, after 30 minutes, the extinction was measured at 460 nm.
By this method about 1 ng/ml cortisol could be demonstrated, which means an increase in sensitivity by a factor 10.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3236732 *||Jan 22, 1962||Feb 22, 1966||Edward R Arquilla||Pregnancy test method and immunological indicator therefor|
|US3293146 *||Mar 25, 1964||Dec 20, 1966||Miles Lab||Composition for detecting guanase and process for diagnosing viral hepatitis therewith|
|US3293147 *||Aug 17, 1964||Dec 20, 1966||Cornell Res Foundation Inc||Measuring the presence of enzyme reactions|
|US3472738 *||Jun 12, 1967||Oct 14, 1969||Weston Lab Inc||Test implement for detecting peroxidase|
|US3509019 *||May 16, 1967||Apr 28, 1970||Fmc Corp||Diallyl phthalate decorative laminates|
|US3519538 *||Sep 5, 1968||Jul 7, 1970||Corning Glass Works||Chemically coupled enzymes|
|US3555143 *||Jun 2, 1967||Jan 12, 1971||Pharmacia Ab||Method for the determination of proteins and polypeptides|
|US3565987 *||Oct 20, 1967||Feb 23, 1971||Organon||Immunochemical determinations of antigens and antibodies|
|US3592888 *||Jan 19, 1968||Jul 13, 1971||Mount Sinai Hospital Research||Radioimmunoassay of angiotensin and renin activity|
|US3615222 *||Sep 4, 1968||Oct 26, 1971||New England Nuclear Corp||Method and apparatus for measuring the amount of a component in a biological fluid|
|US3639558 *||Feb 19, 1968||Feb 1, 1972||Louis Csizmas||Immunological reagent particles having proteinaceous materials covalently bonded thereto|
|US3646346 *||Dec 26, 1968||Feb 29, 1972||Pharmacia Ab||Antibody-coated tube system for radioimmunoassay|
|US3652761 *||Sep 4, 1969||Mar 28, 1972||Corning Glass Works||Immunochemical composites and antigen or antibody purification therewith|
|US3654090 *||Sep 24, 1968||Jul 20, 1982||Title not available|
|US3720760 *||Sep 6, 1968||Feb 7, 1984||Pharmacia Ab||Title not available|
|US3775536 *||Mar 17, 1972||Nov 27, 1973||Hoffmann La Roche||Opium alkaloid antigens and antibodies specific therefor|
|US3778948 *||Oct 2, 1970||Dec 18, 1973||R Berthier||Installation for controlling the condition of water in concrete structures|
|US3779116 *||Feb 16, 1972||Dec 18, 1973||Hill Acme Co||Shearing apparatus|
|US3790663 *||Jul 7, 1970||Feb 5, 1974||Us Health||Preparation of dry antiserum coated solid-phase for radioimmunoassay of antigens|
|US3791932 *||Jan 27, 1972||Feb 12, 1974||Akzona Inc||Process for the demonstration and determination of reaction components having specific binding affinity for each other|
|US3839153 *||Dec 10, 1971||Oct 1, 1974||Akzona Inc||Process for the detection and determination of specific binding proteins and their corresponding bindable substances|
|US3850752 *||Oct 29, 1971||Nov 26, 1974||Akzona Inc||Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically|
|US3903905 *||Oct 9, 1973||Sep 9, 1975||Gillette Co||Hair drying and styling apparatus|
|US4001583 *||Oct 4, 1974||Jan 4, 1977||Barrett M James||Covalently bound biological substances to plastic materials and use in radioassay|
|US4016043 *||Sep 4, 1975||Apr 5, 1977||Akzona Incorporated||Enzymatic immunological method for the determination of antigens and antibodies|
|US4069352 *||Jul 2, 1976||Jan 17, 1978||Baxter Travenol Laboratories, Inc.||Immunoadsorbent polymeric material and method of making same|
|US4154795 *||Jul 21, 1977||May 15, 1979||Dynatech Holdings Limited||Microtest plates|
|AU468151B2 *||Title not available|
|BE779209A2 *||Title not available|
|CA958314A *||Feb 7, 1972||Nov 26, 1974||Akzona Inc||Process for the demonstration and determination of reaction components having specific binding affinity for each other|
|CA1040082B *||May 11, 1978||Oct 10, 1978||Antonius H.W.M. Schuurs||Process for the demonstration and determination of reaction components having specific binding affinity for each other|
|CH573115A5 *||Title not available|
|DE2206103A1 *||Feb 9, 1972||Aug 24, 1972||Organon Nv||Title not available|
|DK58072C||Title not available|
|DK127200B *||Title not available|
|DK131400B *||Title not available|
|DK140268B *||Title not available|
|DK150170B *||Title not available|
|ES399608A1 *||Title not available|
|FI34172A *||Title not available|
|FI44785B *||Title not available|
|FI53894B *||Title not available|
|FR1588874A *||Title not available|
|FR2126760A5 *||Title not available|
|GB1363565A *||Title not available|
|JP5214295B2||Title not available|
|JPS5214295A *||Title not available|
|MX125020A *||Title not available|
|NL154600B *||Title not available|
|NL6812559A *||Title not available|
|NL7016396A *||Title not available|
|NL7018838A *||Title not available|
|NL7101728A *||Title not available|
|NO127685B *||Title not available|
|SE149872C *||Title not available|
|SE341239B *||Title not available|
|SE451162B *||Title not available|
|ZA7200548A *||Title not available|
|1||"Rinsho Kensa" (Clinical Test), 20(9) at 29-35 (Sep. 15, 1976). _|
|2||A. Dohlwitz et al., "Studies on Antibody Formation in Patients Treated with L-Asparaginase, reported in Experimental and Clinical Effects of L-Asparaginase" (ed. E. Grundman et al., Springer-Verlag, New York and Berlin, 1979) at 198-203._|
|3||A. E. Gurvich et al., "Use of Antibodies on an Insoluble Support for Specific Detection of Radioactive Antigens", Nature 203 at 648-649 (1964)._|
|4||A. H. W. M. Schuurs and B. K. van Weemen, "Enzyme-Immunoassay; A Powerful Analytical Tool", J. Immunoassay 1 at 229-249 (1980)._|
|5||A. H. W. M. Schuurs and B. K. van Weemen, "Enzyme-Immunoassay; A Powerful Analytical Tool", Mitt. Disch. Ges. Klin. Chem. 10 at 22-31 (1979)._|
|6||*||A. H. W. M. Schuurs and B. K. van Weemen, "Principles En Toepassingen van Enzym-Immunologische Bepalingen", Meded. Ned Ver. Klin. Chem. 2 at 35-42 (1977). _|
|7||*||A. H. W. M. Schuurs and B. K. van Weemen, "Principles of Heterogeneous Enzyme Immunoassays (EIA or ELISA)", Enzyme Immunoassay Workshop, Wolfgang Vogt, Ed., vol. 1977, at 4-9 (1978)._|
|8||A. H. W. M. Schuurs and B. K. Van Weemen, "Prinzip des Heterogenen enzymimmunoassays (EIA oder ELISA)", Ensymimmunossay; Grundlagen und Praktische Anwendung (Workshop `Enzymimmunoassay` im Rahmen des Kongresses Fuer Laboratoriumsmedizin, May 15 to May 19, 1977, Berlin); Stuttgart, Thieme, at 4-9 (1978; W. Vogt (Hrsg.). _|
|9||*||A. H. W. M. Schuurs and C. J. van Wijngaarden, "A Modified Haemagglutination Inhibition Test and Its Application for the Estimation of Human Luteinizing Hormone in Unconcentrated Urine", Acta. Endocrinol., Suppl. 141 at 13-31 (1970). _|
|10||*||A. H. W. M. Schuurs and C. J. van Wijngaarden, "A Modified Haemagglutination Inhibition Test for Estimating Human Follicle-Stimulating Hormone (HFSH) in Unprocessed Urine", J. Clin. Endocrinol. Metab. 40 at 619-628 (1975)._|
|11||A. H. W. M. Schuurs and C. J. van Wijngaarden, "A Modified Haemagglutination Inhibition Test for the Estimation of FSH in Unconcentrated Urine"; Abstract of Paper Presented at the 13th Federal Meeting of the "Medisch-Biologishe Verenigingen", Amsterdam, Apr. 6-8, 1972, Abst. No. 308 (Original in Dutch)._|
|12||*||A. H. W. M. Schuurs and C. J. van Wijngaarden, "Estimation of Follicle Stimulating Hormone (FSH) in Unconcentrated Urine by a Modified Haemagglutination Inhibition Test", Scand. J. Clin. Lab. Invest. 29, Suppl. 126 (1972), Abstr. No. 24.4._|
|13||*||A. H. W. M. Schuurs and G. Wolters, "Hepatitis B Surface Antigen and Human Serum Proteins", Am. J. Med. Sci. 270 at 173-177 (1975)._|
|14||*||A. H. W. M. Schuurs and J. Kacaki, "Reserved Haemagglutination Test for the Detection of Hepatitis B Antigen", Vox. Sang. 27 at 97-114 (1974)._|
|15||A. H. W. M. Schuurs and K. W. Van Pondman, "Separation of Skin-Sensitive and Complement-Fixing Antibodies From Guinea Anti-Bovine Insulin Sera", Int. J. Immunochem. 2 at 67-70 (1965)._|
|16||A. H. W. M. Schuurs and M. Van der Waart, "Towards the Development of Radioenzyme-Immunoassay (REIA)D", Z. Anal. Chem. 279 at 142 (1976)._|
|17||A. H. W. M. Schuurs and R. Assendorp, "The Early Diagnosis of Pregnancy: Experience With a New Immunochemical Pregnancy Test (Pregnosticon Planotest)", Med. Gynaec. Sociol. 2, No. 9 at 6-11 (1967)._|
|18||A. H. W. M. Schuurs, "Agglutination Inhibition Reactions for the Determination of Gonadotrophins", Acta. Endocrinol., Suppl. 142 at 95-112 (1970)._|
|19||*||A. H. W. M. Schuurs, "Diagnostic Test Kits for the Determination of Human Gonadotrophins", Research within Akzo, Arnhem, Akzo at 69-72 (1973)._|
|20||A. H. W. M. Schuurs, "Estimation of LH in Unconcentrated Urine by a Modified Hemaagglutination Inhibition Reaction", J. Endocrin. 43:xx (1969)._|
|21||A. H. W. M. Schuurs, "Estimation of LH in Unconcentrated Urine by a Variation of the Passive Haemagglutination Inhibition Reaction," Acta. Endocrinol. (KbH.), Suppl. 119 at 120 et seq. (1967)._|
|22||A. H. W. M. Schuurs, "Immunochemische Bepalingen van Organische Verbindingen," Chem. Weekbl. 71, No. 18 at 23-25 (1975)._|
|23||A. H. W. M. Schuurs, "Radio- and Enzyme-Immunoassays of Drugs", Abstract of Paper Presented at 6th European Workshop on Drug Metabolism, Leiden, Jun. 18-23, 1978, Abstr. No. 123._|
|24||A. H. W. M. Schuurs, A. Delver, C. J. van Wijngaarden and F. J. Verbon, "Statistically Designed Haemagglutination Inhibition Tests," J. Immunol Meth. 1 at 133-144 (1972)._|
|25||A. H. W. M. Schuurs, B. K. Van Weemen, H. Hell and B. C. Van Goverde, "Purification, Characterization and Immunochemical Properties of Human Chorionic Gonadotropin", Nature 212 at 261-262 (1966)._|
|26||A. H. W. M. Schuurs, E. de Jager, J. D. H. Homan, "Studies on Human Chorionic Gonadotrophin. III. Immunochemical Characterization", Acta. Endocrinol. (Copenhagen) 59 at 120-138 (1968)._|
|27||A. H. W. M. Schuurs, P. J. Keller and K. Thomas, "A Modified Haemagglutination Inhibition Test for Estimating LH in Unconcentrated Urine; Comparison of the Method with Various Bioassays and with the Radioimmunoassay," Hormones, Lipids and Miscellaneous; 7th Int. Congr. Clin. Chem.; Geneva/Evian, vol. 3; Karger, Basel at 201-206 (1970)._|
|28||A. M. G. Bosch, D. M. Dijkhuizen, A. H. W. M. Schuurs and B. K. van Weemen, "Enzyme Immunoassay for Total Oestrogens in Pregnancy Plasma or Serum", Clin. Chim. Acta 89 at 59-70 (1978)._|
|29||A. M. G. Bosch, H. van Hell, J. A. M. Brands and A. H. W. M. Schuurs, "Application of Enzyme-Immunoassay to Steroid and Protein Hormones", Abstract of Paper Presented at Quantitative Enzyme Immunoassays; Principles and Clinical Applications; Proceedings of the 1st Conference; Glasgow, 1978. Abstr. No. 6. _|
|30||A. M. G. Bosch, H. van Hell, J. A. M. Brands, B. K. van Weemen and A. H. W. M. Schuurs, "Enzyme-Immunoassay and its Application to the Determination of Protein and Steroid Hormones", Acquisitions recentes en Radioimmunologie; Compte-Rendus du IIIe Colloque International de Radioimmunologie; at Lyon, 9-30-76 to 10-2-76. Z. Pl., Z. Uitg., (1978) at 387-396 (1978)._|
|31||*||A. M. G. Bosch, H. van Hell, J. A. M. Brands, B. K. van Weemen and A. H. W. M. Schuurs, "Methods for the Determination of Total Estrogens (TE) and Human Placental Lactogen (HPL) in Plasma of Pregnant Women by Enzyme-Immunoassay (EIA)", Clin. Chem. 21 at 1009 (1975), No. 358. _|
|32||*||A. M. G. Bosch, H. van Hell, J. A. M. Brands, B. K. van Weemen, and A. H. W. M. Schuurs, "Recent Advances in Radio-Immunology", at 387 (1977)._ _|
|33||A. M. G. Bosch, H. van Hell, J. Brands and A. H. W. M. Schuurs, "Specificity, Sensitivity and Reproducibility of Enzyme-Immunoassays," Enzyme Labelled Immunoassay Horm. Drugs, Proc. Int. Symp. (S. B. Pal. ed.), de Gruyter, Publisher, Berlin, at 175-187 (1980)._|
|34||A. M. G. Bosch, H. van Hell, J. Brands and A. H. W. M. Schuurs, "Specificity, Sensitivity and Reproductibility of Enzyme-Immunoassays", Enzyme Labelled Immunoassay of Hormones and Drugs; S. B. Pal (Ed.), Berlin, De Gruyter, at 175-187 (1978)._|
|35||A. M. G. Bosch, H. van Hell, J. Brands, A. H. W. M. Schuurs and B. K. van Weemen, "Enzyme-Immunoassay for Hormones; Preparations of Tracer; Comparison with Radioimmunoassay", Immunoenzymatic Assay Techniques; Proceedings of a European Workshop sponsored by the Comm. of the Europ. Commun., as advised by the Comm. on Med. and Public Health Res., R. Malvano (Ed).; held in Tirrenia (PISA), Apr. 23-27, 1979, The Hague, Nijhoff, 1980; Developments in Clinical Biochemistry 1 at 1.(1980)._|
|36||A. M. G. Bosch, W. H. J. M. Stevens, C. J. van Wijngaarden and A. H. W. M. Schuurs, "Solid Phase Enzyme-Immunoassay (EIA) of Testosterone", Fresenius Z. Anal. Chem. 290 at 98 (1978)._|
|37||A. S. Hamblin, R. A. Wolstewcroft, D. C. Dumonde, F. den Hollander, A. H. W. M. Schuurs, B. M. Backhouse, D. O'Connell and F. Paradinas, "The Potential of Lymphokines in the Treatment of Cancer," In: International Symposium on Biological Preparations in the Treatment of Cancer; Proceedings of the 34th Symposium Organized by the International Association of Biological Standardization and Held at the royal college of Physicians, London, Apr. 13-15, 1977, at 355-341. Basel, Karger (1978), A. H. Griffith and R. H. Regamey (Eds.), Developments in Biological Standardization, vol. 38. _|
|38||A. Schuurs and B. van Weemen, "Enzyme-Immunologische Bestimmungsverfahren", Diagn. Intensivther. 4, No. 2 at 17-21 (1979)._|
|39||*||A. Schuurs and J. Kacaki, "Der Umgekehrte Haemagglutinattiontest fuer Hepatitis B-Antigen (The Reversed Haemagglutination Test for Hepatitis B Antigen)", Forschungsergebnissb der Transfusionsmedizin und Immunhaematologte; Berlin, Medicus (1974) at 645-652, Bericht Des 16, Kongresses Der Durtschen Gesellschaft Fuer Bluttransfusion vom 28 Bis 31 Mai 1974 in Berlin; M. Matthes and V. Nagel (Hrsg.)._|
|40||A. Schuurs and J. Kacaki, "Reversed Haemagglutination Test for Hepatitis B Antigen", International Congress, Ninth, on Tropical Medicine and Malaria, Athens, 14<Oct. 1973. vol 2: Abstracts of Communications, Athens, at 164 (1973)._|
|41||A. Schuurs, Introduction to the Microsymposium "Elisa's Vlucht: Toepassingen van de Enzyme-Immunoassay", abstract of Paper Presented at the 19th Dutch Federative Meeting of Med. Biol. Vereningingen; Rotterdam, 1978, at 50._|
|42||*||Addison et al., "The Immunoradiometric Assay", Radioimmunoassay Methods, Churchhill Livingstone, Edinburgh, (1971), pp. 447-461.|
|43||*||Addison et al., "Two Site Assay of Human Growth Hormone", Hormone and Metabolic Research, vol. 3, No. 1, (1971), pp. 59-60.|
|44||*||Avrameas et al., "The Cross-Linking of Proteins with Glutaraldehydes and its Use for the Preparation of Immunoadsorbents", Immunochemistry, vol. 6, (1969), pp. 53-66.|
|45||*||Avrameas, "Coupling of Enzymes to Proteins with Glutaraldehyde", Immunochemistry, vol. 6, (1969), pp. 43-52.|
|46||*||Avrameas, "Immunoenzyme Techniques Enzymes as Markers for the Localization of Antigens and Antibodies", Int'l. Rev. Cytol., vol. 27, (1970), pp. 349-357.|
|47||*||Avrameas, et al., "Detection of Antibodies and Antigens with the Aid of Enzymes" (Orig.-French, & translation) Bull. Soc. Chim. Biol. 50 at 1169-1178 (1968). _|
|48||*||Avrameas, et al., "Method for the Labelling of Antigens and Antibodies with Enzymes and its Application in Immunodiffusion" (Orig-French, & translation), C.R. Acad. Sc. Paris, t. 262 (6-13 -66) Series D, 2543-2545, Biochime._|
|49||*||Axen et al., "Chemical Coupling of Peptides and Proteins to Polysaccharides by Means of Cyanogen Halides", Nature, vol. 214, (1967), pp. 1302-1304.|
|50||B. E. P. Murphy, "Some Studies of the Protein Binding of Steroids and Their Application to the Routine Micro and Ultramicro Measurement of various Steroids in Body Fluids by Competitive Protein-Binding Radioassay," J. Clin. Endo. and Metab. 27 (7) at 973-990 (1967)._|
|51||*||B. K. van Weeman and A. H. W. M. Schuurs, "Enzyme-Immunoassay for Oestrogens", Abstr. Commun. Presented at the 8th Meet. Fed. Eur. Biochem. Soc., 20-25 Aug. 1972, Abstr. No. 835. _|
|52||B. K. van Weemen and A. H. W. M. Schuurs, "Enzyme-Immunoassay; General Aspects", In: Enzyme-Immunoassay; Proc. of Symp. (Held in the Dr. Saal van Zwanenberg Auditorium, Oss, Sep. 24, 1976), Oss, Organon (1976), at 7-15 (B. K. van Weemen, Ed.)._|
|53||*||B. K. van Weemen and A. H. W. M. Schuurs, "Immunoassay Using Antibody-Enzyme Conjugates." FEBS Letters 43 at 215-218 (1974). _|
|54||*||B. K. van Weemen and A. H. W. M. Schuurs, "Immunoassay Using Antigen-Enzyme Conjugates", FEBS Letters 15 at 232-236 (1971). _|
|55||B. K. van Weemen and A. H. W. M. Schuurs, "Immunoassay Using Hapten-Enzyme Conjugates," FEBS Letters 24 at 77-81 (1972)._|
|56||B. K. van Weemen and A. H. W. M. Schuurs, "Immunochemische bepalingsmethoden voor geneesmiddeln", Pharm. Weekly 115 at 797-801 (1980)._|
|57||*||B. K. van Weemen and A. H. W. M. Schuurs, "Prinzip des Enzym-Immunoassay", Verlag Chem. (Weinhem, Ger.) at 96-101 (1977)._|
|58||*||B. K. van Weemen and A. H. W. M. Schuurs, "Specificity and Sensitivity of Oestrogen Enzyme Immunoassays". Abstract of Paper Read at 1st International Symposium on Immunoenzymatic Techniques (INSERM) Clichy (France), Apr. 2-(1975), 1 p._|
|59||*||B. K. van Weemen and A. H. W. M. Schuurs, "The Influence of Heterologous Combinations of Antiserum and Enzyme-Labeled Estrogen on the Characteristics of Estrogen Enzyme-Immunoassays". Immunochemistry 12 at 667-670 (1965)._|
|60||*||B. K. van Weemen and A. H. W. M. Shuurs, "Enzyme-Immunoassay: General Aspects", Enzyme-Immunoassay Symposium, Sep. 24, 1976; Abstracts, Oss, Organon, at 6-7 (1976)._|
|61||B. K. van Weemen and J. Kacaki, "A Modified Hemagglutination Inhibition Test for Rubella Antibodies, Using Standardized, Freeze-Dried Reagents" (Report of a Comparative Multi-Centre Trial), J. Hyg. (CAMB) 77 at 31.increment.(1976)._|
|62||B. K. Van Weemen, "Enzyme-Immunoassay. The Use of Enzyme-Labeled Compounds for Immunoassays of Human Chorionic Gonadotrophin, Leutinizing Hormone and Oestrogens". Thesis, Groningen, 161 p. (1974)._|
|63||B. K. van Weemen, "Techniques Immuno-Enzymatiques," Ann. Biol. Clin. (Paris) 33 at 238 (1975). _|
|64||B. K. van Weemen, A. Bosch, E. Dawson and A. Schuurs, "Enzyme-Immunoassay of Steroids; Possibilities and Pitfalls," Abstr. of Paper Presented at 5th International Congress on Hormonal Steroids; New Delhi, Oct. 29-Nov. 4, 1978 at 16._|
|65||B. K. van Weemen, A. Bosch, J. Brands, H. van Hell, L. Kuijpers, A. Schuurs and G. Wolters, "Enzyme-Immunoassays for HBsAg, HPL and Estrogens in Serum", Clin. Biochem. 10, No. 2 at 6-7 (1977)._|
|66||B. K. van Weemen, A. M. G. Bosch, E. C. Dawson and A. H. W. M. Schuurs, "Enzyme-Immunoassay of Steriods; Possibilities and Pitfalls", J. Steroid Biochem. 11 at 147-151 (1979)._|
|67||B. K. van Weemen, A. M. G. Bosch, E. C. Dawson, H. van Hell and A. H. W. M. Schuurs, "Enzyme Immunoassay of Hormones", Scand. J. Immunol. 8, Suppl. 7 at 73-82 (1978)._|
|68||*||B. K. van Weemen, A. M. G. Bosch, H. van Hell, J. A. M. Brands, G. Wolters, L. P. C. Kuijpers and A. H. W. M. Schuurs, "Enzyme-Immunoassay", Organisation des Laboratories et Interpretation des Resultats; Biologie Prospective; Compies Bendus du Troisieme Colloque International, Organise Par L'Association Recherche Biochimique et Pharmaceutique Lorraine, 1975, Pont-a-Mousson (Fr.); G. Siest (Ed.); Paris, Expansion Sci. Fr., (1977) at 615-621._|
|69||B. K. Van Weemen, A. M. G. Bosch, H. van Hell, J. A. M. Brands, G. Wolters, L. P. C. Kuypers and A. H. W. M. Schuurs, "Enzyme Immunoassay", Organisation des Laboratoires-Biologie Prospective, IIIe Collogue de Pont-a-Mousson at 615-621 (1975)._|
|70||B. K. Weemen and A. H. W. M. Schuurs, "Sensitivity and Specificity of Hapten Enzyme-Immunoassays", Immunoenzymatic Techniques; Proceedings of the First International Symposium on Immunoenzymatic Techniques, held in Paris, 2-4 Apr., 1975; Amersterdam, N. Holl. Publ. 1976 at 125-133. Eds. G. Feldmann, P. Druet, J. Bignon.|
|71||Bauke K. Van Weemen and Anton H. W. M. Schurrs, "Principles of Enzyme-Immunoassays", Principles of Enzymatic AnalysisWeinheim, Verl. Chemie at 93-98 (1978), H. U. Bergmeyer and K. Gawehn (Eds.)_|
|72||*||Catt et al., "A Solid Phase Disc Radioimmunoassay for Human Growth Hormone", J. Lab. Clin. Med., vol. 70, (1967), pp. 820-830.|
|73||*||Catt et al., "Disc Solid-Phase Radioimmunoassay of Human Luteinizing Hormone", J. Clin. Endocin. Metab., vol. 28, No. 1, (1968), pp. 121-126.|
|74||*||Catt et al., "Solid Phase Radioimmunoassay", Nature, vol. 213, (1967), pp. 825-827.|
|75||*||Catt et al., "Solid-Phase Radioimmunoassay in Antibody-Coated Tubes", Science, vol. 158 (1967), pp. 1570-1571.|
|76||*||Catt et al., "Solid-Phase Radioimmunoassay of Human Growth Hormone", Biochem. J., vol. 100, (1966), pp. 31c-33c.|
|77||*||Cuatrecasas et al., "Selective Enzyme Purification by Affinity Chromatography", Proc. N. A. S., vol. 61, (1968), pp. 636-643.|
|78||*||Cuatrecasas, "Protein Purification by Affinity Chromatography", J. Biol. Chem., vol. 245, No. 12, (1970), pp. 3059-3065.|
|79||D. C. Dumonde, M. S. Pulley, D. O'Connell, B. M. Southcott, M. R. G. Robinson, F. J. Paradinas, C. C. Rigby, F. den Hollander, A. Schuurs and R. W. de Briun, "Clinical Effects of Long-Term Lymphokine Injections in Patients With Advanced Carcinoma", Int. J. Immunopharmacol. 2 at 190-191 (1980)._|
|80||*||Day, Advanced Immunochemistry, Williams & Williams Co., Baltimore, (1972), pp. 188, 316.|
|81||*||Dr. A. H. W. M. Schuurs, "Practical Results with Pregnosticon and Pregnosticon Planotest", Organorama 4(4) at 4-10 (1967). _|
|82||*||Dr. A. H. W. M. Schuurs, "Pregnancy Diagnosis and Assay of Chorionic Gonadotrophin by Immunochemical Methods", Organorama 4 Nos. 3 and 4 (1969)._|
|83||E. C. Dawson, A. E. H. C. Denissen and B. K. van Weemen, "A Simple and Efficient Method for Raising Steroid Antibodies in Rabbits", Steroids 31 at 357-366 (1978)._|
|84||E. C. Dawson, A. M. G. Bosch and B. K. van Weemen, "Enzyme-Immunoassay for Steroids," In: Research on Steroids; vol. VIII; Proceedings of the Serono Sympusia, vol. 21, London Acad. Press at 139-146 (1979), eds.: A. Klopper, L. Lerner, H. J. van der Molen, A. D. Transactions of the 8th Meeting of the International Study Group for Steroid Hormones. _|
|85||*||Eisen, Immunology, Chapter 3, "Reactions with Soluble Macromolecules", (1974), pp. 370-371.|
|86||*||Engvall et al., "Enzyme-Linked Immunosorbent Assay, ELISA" Protides of the Biological Fluids, Proceedings of the Nineteenth Colloquium Brugge, (Peeters, H. ed.), Pergamon Press, Oxford, (1971), p. 55.|
|87||F. C. den Hollander and A. H. W. M. Schuurs, "Application of the `Double Antibody Solid Phase` Method to Radioimmunoassays of Insulin and Oestrogens", Abstract of Paper presented at the 13th Federal Meeting of the Medisch-Biologische Verenigingen, Amsterdam, Apr. 6-8, Abst. No. 146 (Original in Dutch)._|
|88||*||F. C. den Hollander and A. H. W. M. Schuurs, "Radioimmunoassay of Oestrogens (E) Using the `Double Antibody Solid Phase (DASP)` Method ", Scand. J. Clin. Lab. Invest. 29, Suppl. 126 (1972), Abstract No. 14.17.|
|89||F. C. den Hollander et al., "Assessment of Activities of Leukocyte Inhibitory Factor (LIF), and of Antibodies Against LIF", Biochemical Characterization of Lymphokines; Proc. of the 2nd Int. Lymphokine Workshop: Ermatingen (Switz)., A. L. de Weck et al. (Eds.), May 27-31, 1979, New York, Acad. Press at 109-111 (1980)._|
|90||F. C. den Hollander, A. H. W. M. Schuurs and H. van Hell, "Radioimmunoassays for Human Gonadotrophins and Insulin, Emplying a Double-Antibody Solid-Phase Technique," J. Immunol. Meth. 1 at 247-262 (1972)._|
|91||*||F. C. den Hollander, B. K. van Weemen and G. F. Woods, "Specificities of Antisera Against Estrogens Linked to Albumin at Different Positions" (C.sub.6, C.sub.11, C.sub.16, C.sub.17); Steroids 23 at 549-560 (1974)._|
|92||F. C. den Hollander, B. K. van Weemen and G. F. Woods, "Specificities of Antisera Against Estrogens Linked to Albumin at Different Positions" (C6, C11, C16, C17); Steroids 23 at 549-560 (1974)._|
|93||G. E. Abraham et al., "Solid Phase Radioimmunoassay of Serum Estradiol-17β; A Semi-Automated Approach", in Immunologic Methods of Steroid Determination (F. G. Peron et al.; editors, Meredith Corp. New York 1970) at 87-112 (1970)._|
|94||G. Wolters, L. Kuijpers and A. Schuurs, "Detection of Human Antibodies to Hepatitis B Surface Antigen (HBsAG) by an Enzyme-Immunoassay for HBsAG", J. Clin. Pathol. 32 at 1264-1271 (1979)._|
|95||G. Wolters, L. Kuijpers and A. Schuurs, "Enzyme-Immunoassay as a Diagnostic Tool in Viral Hepatitis B", Abst. of Paper Presented at Meeting of the European Group for Rapid Laboratory Viral Diagnosis and 16th Symposium European Association Against Virus diseases; Amsterdam Sep. 6-9, 1977._|
|96||*||G. Wolters, L. Kuijpers, J. Kacaki and A. H. W. M. Schuurs, Forschungergebnisse der Transfusionsmedizin und Immunhaematologie (Hand 3: Bericht des 17), Kongresses der Deutschen Gesellschaft Fuer Bluttransfusion und Immunhaematologie , vom 26, Bis 29 Apr. 1976 in Frankfurt._|
|97||G. Wolters, L. Kuijpers, J. Kacaki and A. Schuurs, "Solid Phase Enzyme Immunoassay for Detection of Hepatitis B Surface Antigen", J. Clin. Pathol. 29 (10) at 873-879 (1976)._|
|98||G. Wolters, L. P. C. Kuijpers, A. H. W. M. Schuurs and J. Kacaki, "Enzyme-Immunoassay (EIA) of Hepatitis B. Surface Antigen (HBsAG) in Microtiter Plates," Z. Anal. Chem. 279 at 144 (1976). _|
|99||*||G. Wolters, L. P. C. Kuijpers, A. H. W. M. Schuurs, "Enzyme Immunoassay (EIA) for HBsAg in Microtiter Plates", Hepatitis Scientific Memoranda (July 1975)._|
|100||G. Wolters, L. P. C. Kuijpers, J. Kacaki and A. H. W. M. Schuurs, "Enzyme-Immunoassay for HBsAg", Lancet II at 690 (1976). _|
|101||*||G. Wolters, L. P. C. Kuijpers, J. Kacaki and A. H. W. M. Schuurs, "enzyme-Immunoassay for Hepatitis B Surface Antigen", Abstract of paper Presented at 220 Convegno di studi della societa italiana di immunoematulogia e Associazione Italiana Dei Centri Trasfusionali at 14-18 Sep., 1977, Abstr. No. 26._|
|102||*||G. Wolters, L. P. C. Kuijpers, J. Kacaki and A. H. W. M. Schuurs, "Enzyme-Immunoassay for Hepatitis B Surface Antigen", Enzyme-Immunoassay; Proc. of a Symp. (Held in the Dr. Saal van Zwanenberg Auditorium, Oss, Sep. 24, 1976), Oss, Organon At 77-88 (1978). B. K. van Weemen (Ed.)._|
|103||G. Wolters, L. P. C. Kuijpers, J. Kacaki and A. H. W. M. Schuurs, "Enzyme-Linked Immunosorbent Assay for Hepatitis B Surface Antigen", J. Infect. Dis. 136, Suppl., Suppl. 311-S, Suppl. 317 (1977)._|
|104||*||G. Wolters, L. P. C. Kuijpers, J. Kacaki and A. Schuurs, "Enzyme-Immunoassay for Hepatitis H Surface Antigen", Enzyme-Immunoassay Symposium, Sep. 24, 1976; Abstracts, Oss, Organon, 1976 at 20-21. _|
|105||*||G. Wolters, P. Thal, A. H. W. M. Schuurs and J. Kacaki, "Hepanosticon in Screening for HBsAg", Lancet 1 at 1193-1194 (1975)._|
|106||G. Wolters, P. Thal, J. Kacaki and A. H. W. M. Schuurs, "Screening for HBsAg by Hepanosticon in Microplates", Biomed. Express 25 at 72 (1976)._|
|107||*||Geoffrey Scott, et al., "Electron-microscopic Study of the Formation of Antibodies with the Aid of Alkaline Phosphatase Used like an Antigen", C. R. Acad. Sc. Paris, (Series D), 266 at 746-748 (12 Feb. 1968), and translation._|
|108||*||Gerloff et al., "Precipitation of Radiolabelled Poliovirus with Specific Antibody and Antiglobulin", J. Immunol., vol. 89, (1962), pp. 559-570.|
|109||*||Girard et al., "Attempts to Use Polymerized Antigen for the Isolation and Labelling of Specific Antibodies", Radioimmunoassay Methods, Churchhill Livingstone, Edinburgh, (1971), pp. 467-488.|
|110||*||Gocke et al., "Hepatitis Antigen", The Lancet, (May 31, 1969), pp. 1055-1059.|
|111||H. van Hell and A. H. W. M. Schuurs, "Further Studies on the Purification and Characterisation of Human Chorionic Gonadotrophin", Gonadotrophins and Ovarian Development; Proc. of the Two Workshop Meetings on the Chemistry of the Human Gonadotrophins and on the Development of the Ovary in Infancy; Birmingham, 1969. Edinburgh, Livingston; W. R. Butt, A. C. Crooke and M. Ryle (Eds.) at 70-76 (1970).|
|112||*||H. van Hell and A. H. W. M. Schuurs, "Immunochromatographic Purification of Human Urinary Luteinizing Hormone", J. Endocrinol. 54 at 171-172 (1972)._|
|113||H. van Hell and A. H. W. M. Schuurs, "Purification and Characterization of Urinary Luteinizing Hormone", Abstract of Paper Presented at the 13th Federal Meeting of the Medisch-Biologische Verenigingen", Amsterdam, Apr. 6-8, 1972, Abstract No. 132, (Original in Dutch). _|
|114||H. van Hell, A. H. W. M. Schuurs and F. C. den Hollander, "Purification and Some Properties of Human Urinary FSH and LH", Gonadotropins, New York, Wiley-Interscience; B. B. Saxena, C. G. Belling and H. M. Gandy (Eds.) at 185-199 (1972)._|
|115||H. van Hell, A. M. G. Bosch, J. A. M. Brands, A. H. W. M. Schuurs and B. K. Van Weeman, "Der Enzymimmunoassay in Der Endokrinologie", Praktische Anwedung des Enzym-Immunoassays in Klinishcher Chemie und Serologie 10-19; W. Vogt (Ed.), Stuttgart, Thieme (1979)._|
|116||H. van Hell, A. M. G. Bosch, J. A. M. Brands, B. K. van Weemen and A. H. W. M. Schuurs, "Pregnancy Monitoring with Enzyme-Immunoassay for Human Placental Lactogen and Total Oestrogens," Z. Anal. Chem. 279 at 143 (1976)._|
|117||*||H. van Hell, A. M. G. Bosch, J. A. M. Brands, B. K. van weemen, A. H. W. M. Schuurs, "Enzyme-Immunoassays (EIAs) for Protein and Steroid Hormones", Abstract of Paper presented at Recenti Progressi in Radioimmunologia Clinica, Brescia at 11-12 Mar., 1977, 2 p. _|
|118||H. van Hell, J. A. M. Brands and A. H. W. M. Schuurs, "Enzyme-Immunoassay of Human Placental Lactogen", Clin. Chim. Acta. 91 at 309-316 (1979)._|
|119||H. van Hell, J. A. M. Brands, A. M. G. Bosch, B. K. van Weemen and A. H. W. M. Schuurs, "Enzyme-Immunoassay for Human Placental Lactogen and Total Oestrogens for Use in Pregnancy-Monitoring", Enzyme Immunoassay; Proc. of a Symp. (Held in the Dr. Saal van Zwanenberg Auditorium, Oss, Sep. 24, 1976), Oss, Organon, at 34-40 (B. K. van Weemen, Ed.), 1978._|
|120||H. Verheul, W. Stimson, F. den Hollander and A. Schuurs, "Prophlaxtic and Therapeutic Effects of Nandrolone and its Decanoate Ester (Deca-Durabolin) in Murine Lupus", Int. J. Immunopharmacol. 2 at 230 (1980)._|
|121||*||Habermann; "Ein Neues Prinzip zur Quantitatives Bestommuny Hochmolecular Antigene (Verknupfungstest) und Seine Anwendung auf Tetanustoxin Serumalbumin und Ovalbumin", Z. Klin. Chem. u. Klin. Biochem., vol. 8, No. 1, (1970), pp. 51-53. Tetanustoxin|
|122||*||Hales et al., "Immunoassay of Insulin with Insulin-Antibody Precipitate", Biochem. J., vol. 88, (1963), pp. 137-146.|
|123||*||Hamolsky et al., "The Thyroid Hormone Plasma Protein Complex in Man. II. A New In Vitro Method for Study of Uptake by Labelled Hormonal Components by Human Erythrocytes", J. Clin. Endocrin. and Metab., vol. 17, No. 1, (1957), pp. 33-44.|
|124||J. H. W. Leuvering, P. J. H. M. Thal, M. van der Waart and A. H. W. M. Schuurs, "Sol Particle Agglutination Immunoassay for Human Chorionic Gonadotrophin," Fresenius Z. Anal. Chem. 301 at 132 (1980)._|
|125||J. H. W. Leuvering, P. J. H. M. Thal, M. van der Waart and A. H. W. M. Schuurs, "Sol Particle Immunoassay (SPIA)", J. Immunoassay 1 at 77-91 (1980)._|
|126||*||J. Kacaki, A. H. W. M. Schuurs, G. Wolters and J. Lalosevic, "Hepatitis-B Antigen in Venereal Diseases", Lancet at 363-364 (1975)._|
|127||J. Kacaki, G. Wolters, L. Kuijpers and A. H. W. M. Schuurs, "Specificity Control in Solid-Phase Enzyme Immunoassay for HGsAg by One-Step in situ Blocking With Human Anti-HBS", J. Clin. Pathol. 30 at 894-898 (1977)._|
|128||J. N. Katchaki, M. van der Waart, T. H. Siem, R. Brouwer and A. H. W. M. Schuurs, "The Occurrence of Antibody Markers of Hepatitis B Virus, Infection in an HBsAG-Negative Blood Donor Population", Vox Sang. 37 at 9-13 (1979)._|
|129||*||J. Pelletier, et al., "Radio-immunological Assay of the Luteinizing Hormone of Sheep. Adjustment of the Assay Technique", C. R. Acad. Sc. Paris. (Series D), 266 at 2291-2294 (10 Jun. 1968) and translation._|
|130||*||J. Pelletier, et al., "Radio-immunological Determination of the Plasma Luteinizing Hormone of Sheep. Comparison with the Biological Determination of LH by the Diminution of Ovarian Ascorbic acid and Example of the Measurements of the LH of the Blood of Ewes", C. R. Acad. Sc. Paris", (Series D)., 266 at 2352-2354, (17 Jun. 1968), and translation._|
|131||*||Jacqueline Dolais, et al., "Determination of the Human Luteinizing Hormone (HLH) in Plasma by Means of the Radio-Immunological Method. LH Strength in the Plasma During the Menstrual Cycle of Normal Women, and During and After the Taking of Oral Contraceptive", C. R. Acad. Sc. Paris, (Series D), 267 at 1162-1165 (30 Sep. 1968), and translation. _|
|132||*||Jacqueline Dolais, et al., "Plasma Determination of the Human Luteinizing Hormone (HLH) by Means of Radio-Immunology. Adjustment of the Determination Technique", C. R. Acad. Sc. Paris, (Series D), 267 at 1105-1108 (23 Sep. 1968) and translation._|
|133||L. Matthyssen, O. Schoenherr, B. Van Weemen, "Rapid Screening for Rubella Antibodies by Enzyme Immunoassay", International Virology 4; Abstracts of the Fourth International Congress for Virology (Hague, Aug. 30-Sep. 6, 1978), Wageningen, Pudoc, 1978 at 626 Abstr. W 504A/2._|
|134||*||M. Marc Stanislawski, "The Use of Peroxidase as a Label in the Immunochemical Quantification of Antigens and Antibodies" (Orig. French, & translation), C.R. Acad. Sci. Paris, 271 at 1452-1455 (Oct. 19, 1970)._|
|135||M. Van de Waart, A. Snelting, J. Cichy, G. Wolters and A. Schurrs, "Enzyme-Immunoassay for Hepatitis B-Related `E` Antigen (HBeAG)", Abstract of Paper Presented at the 19th Dutch Federative Meeting of Med. Biol. Verenigingen; Rotterdam, 1978 at 427._|
|136||*||M. van der Waart and A. H. W. M. Schuurs, "Kanttekeningen Bij de Gevoeligheid van Enzym-Immuno Bepalingen" Meded. Ned. Ver. Klin. Chem. 2 at 141-147 (1977)._|
|137||M. Van der Waart and A. H. W. M. Schuurs, "Nieuwe Ontwikkelingen In Het Gebied van de Enaymimmuunbepalingen", Ned. Tijdschr. Geneeskd. 121 at 1407 (1977). _|
|138||*||M. Van der Waart and A. Schuurs, "The Sensitivity of Enzyme-Immunoassay; Some Facts and Figures", Bull. Schweiz. Ges. Klin. Chem. No. 4 at 9-16 (1977)._|
|139||M. Van der Waart, A. Bosch, G. Wolters, L. Kuijpers, B. van Weemen and A. Schuurs, "Enzyme-Immunoassay; A New Diagnostic Tool", Chem. Rundsch. 30, No. 28 at 1-2 (1977)._|
|140||M. van der Waart, A. Snelting, F. Bruijnis, M. Prins-Bekius, E. Bos, J. Katchaki and A. Schuurs, "Comparison of Enzyme-Labelled F(ABl)2 and IGG conjugates in an Enzyme-Immunoassay for Hepatitis B `E` Antigen," J. Virol. Methods 2 at 85-96 (1980)._|
|141||M. van der Waart, A. Snelting, J. Cichy, G. Wolters and A. Schuurs, "Enzyme-Immunoassay in the Diagnosis of Hepatitis With Emphasis on the Detection of `E` Antigen (HBeAG)", J. Med. Virol. 3 at 43-49 (1978)._|
|142||M. van der Waart, A. Snelting, J. Cichy, G. Wolters and A. Schuurs; "Enzyme-Immunoassay for Hepatitis B Related `E` Antigen (HBsAg)", International Virology 4; Abstracts of the Fourth International Congress for Virology (Hague, Aug. 30-Sep. 6, 1978), Wageningen, Pudoc, 1978, Abstr. W 28/7. _|
|143||M. van der Waart, A. Snelting, J. Cichy, P. Niermeijer, C. H. Gips, J. R. Huizenga and A. Schuurs, "The Hepatitis B Related `E` Antigen-Antibody System as Measured by Enzyme-Immunoassay", Antonie Van Leeuwenhoek 44 at 461-462 (1978)._|
|144||Methods in Immunology and Immunochemistry (ed. by C. A. Williams, et al., Academic Press, New York, 1967), xi-xvii._|
|145||*||Midgley et al., "Radioimmunoassay of Steroids", Karolinska Symposia on Research Methods in Reproductive Endocrinology, 2nd Symposia Steroids Assay by Protein Binding, Mar. 23-25, pp. 520-531.|
|146||*||Midgley et al., "Radioimmunoassays Employing Double Antibody Techniques", Acta. Endocr. (Kph.) Suppl., vol. 142, (1969), pp. 247-256.|
|147||*||Midgley, "Radioimmunoassay: A Method for Human Chorionic Gonadotropin and Human Luteinizing Hormone", Endocrinology, vol. 79, (1966), pp. 10-18.|
|148||*||Miles et al., "An Immunoradiometric Assay of Insulin", Protein and Polypeptide Hormones, Margolius Ed., Excerpta Medica Foundation, Amsterdam, (1968), pp. 61-70.|
|149||*||Miles et al., "Immunoradiometric Assay of Human Growth Hormone", The Lancet, (Aug. 31, 1968), pp. 492-493.|
|150||*||Miles et al., "Labelled Antibodies and Immunological Assay Systems", Nature, vol. 219, (1968), pp. 186-188.|
|151||*||Miles et al., "The Preparation of Properties of Purified .sup.125 I-Labelled Antibodies to Insulin", Biochem. J., vol. 108, (1968), pp. 611-618.|
|152||Miles et al., "The Preparation of Properties of Purified 125 I-Labelled Antibodies to Insulin", Biochem. J., vol. 108, (1968), pp. 611-618.|
|153||*||Miles et al., "The Use of Labelled Antibodies in the Assay of Polypeptide Hormones", J. Nucl. Biol. Med., vol. 13, (1969), pp. 10-13.|
|154||*||Nakane et al., "Enzyme-Labeled Antibodies for the Light and Electron Microscopic Localization of Tissue Antigens", J. Cell. Biology, vol. 33, (1967), pp. 307-318.|
|155||*||Nakane et al., "Enzyme-Labelled Antibodies Preparation and Application for the Localization of Antigens", J. Histochem. Cytochem., vol. 14, No. 12, (1967), pp. 929-931.|
|156||*||Ostrowski et al., "Autoradiographic Detection of Antigens in Cells Using Tritium-Labeled Antibodies", J. Histochem. Cytochem., vol. 18, (1970), pp. 490-497.|
|157||*||P. Guillien, et al., "Combination of Immunofluorescense and Immuno-enzymology for the Detection of Intra-Cellular Antibodies",C. R. Acad. Sc. Paris, (Series D), 267 at 1425-1427 (2 Oct. 1968) and translation._|
|158||P. Nermeyer, G. H. Gips, J. R. Huizenga, M. van der Waart and A. H. W. M. Schuurs, "Preference and Significance of Hepatitis B Antigen and Anti-Hepatitis B Determined by Enzyme Immunoassay in Patients with Acute Chronic and Resolved Hepatitis" Hepato-Gastroenterol 27(5) at 350-355 (1980)._|
|159||*||P. Niermeijer, C. H. Gips, J. R. Huizenga, M. van der Waart, and A. Schuurs, "Preference and Significance of HBeAg and Anti-HBe, Determined by Enzyme Immunoassay, in Patients with Acute, Chronic and Resolved Hepatitis B", Hepato-Gastroenerol 27 at 350-355 (1980)._|
|160||P. Niermeyer; Gips, C. H.; Huizenga, J. R.; Van der Waart, M.; and Schuurs, A. H. W. M., "Preference and Significance of Hepatitis BE Antigen and Anti-Hepatitis BE Determined by Enzyme Immunoassay in Patients with Acute Chronic and Resolved Hepatitis BE,"Hepato-Gastroenterol 27(5) at 350-355 (1980)._|
|161||*||Pierr, Leleux, et al., "Detection of Gonadotropic Cells in the Hypophysis of Rams by Means of an Immunofluorescence Method", C. R. Acad. Sc. Paris, (Series D), 267 at 438-440 (22 Jul. 1968), and translation. _|
|162||*||Porath et al., "Chemical Coupling of Proteins to Agarose", Nature, vol. 215, (1967), pp. 1491-1492.|
|163||R. Assendorp and A. H. W. M. Schuurs, "A Survey of the Initial Clinical Results Obtained With an Immunochemical Test for Measuring Urinary LH-Excretion", Acta. Endocrinol., Suppl. 141 at 185-195 (1970)._|
|164||R. S. Yalow and S. A. Berson, "General Principles of Radioimmunoassay," in Radioisotopes in Medicine, in Vitro Studies (R. L. Hayes et al.; editors, U.S. Atomic Energy Comm., Jun. 1968: Proceedings of Symposium at Oak Ridge Associated Universities Nov. 13-16, 1967) at 7-41 (1968)._|
|165||Radioimmunoassay (Pub. K. K. Asakura Shoten, Japan, Jan. 10, 1970)._|
|166||S. G. Korenman, "Radio-Ligand Binding Assay of Specific Estrogens Using A Soluble Uterine Macromolecule," J. Clin. Endo. Metab. 28(1) at 127-130 (1968)._|
|167||*||Salmon et al., "Sandwich Solid Phase Radioimmunoassay for the Quantitative Determination of Human Immunoglobulins", J. Immunology, vol. 103, No. 1, (1969), pp. 129-137.|
|168||*||Schuurs et al., "Enzyme Immunoassay", Clin. Chim. Acta., vol. 81, (1977), pp. 1-40.|
|169||*||Sercarz et al., "Antigen Binding to Cells Determination by Enzymatic Fluorogenic Group Hydrolysis", Science, vol. 159, (1968), pp. 884-885.|
|170||*||Sidney D. Bradshaw, et al., "Cortisol in the Plasma of Eels, Determined by Fluorimetry and by the Competitive Inhibitions of the Specific Cortisol-Transcortine Bond. The Influence of Various Experimental Conditions", C. R. Acad. Sc. Paris, (Series D), at 894-897 (26 Aug. 1968) and translation. _|
|171||*||Silman et al., Annual Review of Biochem., vol. 35, Part II, (1966), Boyer et al., Ed., Annual Reviews, Palo Alto, p. 902.|
|172||*||Solomon et al., "Radioimmunoassay of ACTH in Plasma", J. Clin. Invest., vol. 47, (1968), pp. 2725-2751.|
|173||*||Spector et al., "Morphine: Radioimmunoassay", Science, vol. 168, (1970), pp. 1347-1348.|
|174||*||Sternberger et al., "The Unlabeled Antibody Enzyme Method of Immunohistochemistry", J. Histochem. Cytochem., vol. 18, No. 5, (1970), pp. 315-333.|
|175||*||Stratis Avrameas, et al., "Detection of Antibodies of Immunocompetent Cells of Animals Immunized with Enzymes", C. R. Acad. Sc. Paris, (Series D), 265 at 302-304 (17 Jul. 1967) and translation._|
|176||*||Stratis Avrameas, et al., "Enzymes Coupled to Proteins: Their Utilization for the Detection of Antigens and Antibodies", C. R. Acad. Sc. Paris, (Series D), 265 at 1149-1152 (16 Oct. 1967), and translation._|
|177||T. C. J. Gribnau, T. van Lith, F. Roeles, C. J. van Wijngaarden, H. van Hell and A. H. W. M. Schuurs, "Immunosorbents based on Halopyrimidine or Reactive Azodye Activated Polysaccharide Matrices," Protides of Biological Fluids; Proceedings of the 27th Colloquium; Broges, Apr. 30-May 3, 1979, at 793-796. Oxford, Pergamon, H. Peeters (Ed.) 1979)._|
|178||T. Gribnau, T. van Lith, A. van Sommeren, F. Roeles, H. van Hell, and A. Schuurs, "Synthesis and Application of Immunosorbents Based on Halopyrimidine or Reactive Azo-Dye Activated Polysaccharides-Influence of Ligand Modification on the Performance of Immunosorbents", Chromatographie d'Affinite et Interactions Moleculaires; Colloque, Strasbourg, Jun. 26-29, 1979, Paris, Inserm, 1979, at 175-186, Inserm vol. 86, J. M. Egly, G. Vincendon and J. P. Zanetta (Eds.)._|
|179||*||Voller et al., "Enzyme Immunoassays in Diagnostic Medicine", Bull. World Health Organ., vol. 53, (1976), pp. 55-65.|
|180||*||Walsh et al., "Detection of Australian Antigen and Antibody by Means of Radioimmunoassay Techniques", J. Infect. Diseases, vol. 121, No. 5, (1970), pp. 550-554.|
|181||*||Wide et al., "Diagnosis of Allergy by an In-Vitro Test for Allergen Antibodies", The Lancet, (Nov. 25, 1967), pp. 1105-1107.|
|182||*||Wide et al., "Radioimmunoassay of Proteins with the Use of Sephadex-Coupled Antibodies", Biochem. Biophys. Acta., vol. 130, (1966), pp. 257-260.|
|183||*||Wide, "Early Diagnosis of Pregnancy", The Lancet, (Oct. 25, 1969), pp. 863-864.|
|184||*||Wide, "Radioimmunoassays Employing Immunosorbents", Acta. Endocr. (Kph.) Suppl., vol. 142, (1969), pp. 207-221.|
|185||*||Wide, "Radioimmunoassays Employing Immunosorbents", Karolinska Symposia on Research Methods in Reproductive Endorcinology, 1st Symposia Immunoassay of Gonadotrophins, Sep. 23-25, 1969, pp. 207-221.|
|186||*||Wide, "Solid Phase Antigen-Antibody Systems", Radioimmunoassay Methods, Churchhill Livingstone, Edinburgh, (1971), pp. 405-443.|
|187||*||Yagi et al., "Immunoelectrophoretic Identification of Guinea Pig Anti-Insulin Antibodies", J. Immunol., vol. 89, No. 5, (1962), pp. 736-744.|
|188||*||Yalow et al., "Immunoassay of Endogenous Plasma Insulin in Man", J. Clin. Invest., vol. 39, (1960), pp. 1157-1175.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5009997 *||Jan 30, 1985||Apr 23, 1991||Shah Vipin D||Two site cross-reaction immunometric sandwich assay method|
|US5047330 *||Jan 6, 1988||Sep 10, 1991||Commissariat A L'energie Atomique||Compound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations|
|US5183743 *||Nov 29, 1991||Feb 2, 1993||Miles Inc.||Chromogenic dibenzoxazepinone and dibenzothiazepinone enzyme substrates|
|US5298401 *||May 5, 1988||Mar 29, 1994||Bernd Binder||Process for the quantitative determination of the function and antigenic concentration of a substance contained in a biological liquid|
|US5374524 *||Apr 27, 1993||Dec 20, 1994||E. I. Du Pont De Nemours And Company||Solution sandwich hybridization, capture and detection of amplified nucleic acids|
|US5391478 *||Feb 21, 1992||Feb 21, 1995||E. I. Du Pont De Nemours And Company||Assay device and immunoassay|
|US5391479 *||Oct 29, 1992||Feb 21, 1995||E. I. Du Pont De Nemours And Company||Method for determining total analyte concentration in a sample having both free and bound analyte|
|US5447837 *||Feb 6, 1989||Sep 5, 1995||Calypte, Inc.||Multi-immunoassay diagnostic system for antigens or antibodies or both|
|US5587294 *||Oct 28, 1994||Dec 24, 1996||Assay Research, Inc.||Method and kit for measuring endogenous cytokines|
|US5637467 *||Mar 29, 1995||Jun 10, 1997||Behringwerke Ag||Heterogeneous assay using a pendulous drop|
|US5877028 *||Mar 31, 1993||Mar 2, 1999||Smithkline Diagnostics, Inc.||Immunochromatographic assay device|
|US5879951 *||Jan 29, 1997||Mar 9, 1999||Smithkline Diagnostics, Inc.||Opposable-element assay device employing unidirectional flow|
|US5998220||Feb 10, 1994||Dec 7, 1999||Beckman Coulter, Inc.||Opposable-element assay devices, kits, and methods employing them|
|US6001968||Aug 17, 1994||Dec 14, 1999||The Rockefeller University||OB polypeptides, modified forms and compositions|
|US6017767||Jun 5, 1995||Jan 25, 2000||Beckman Coulter, Inc.||Assay device|
|US6048837||Jun 7, 1995||Apr 11, 2000||The Rockefeller University||OB polypeptides as modulators of body weight|
|US6124448||Jun 7, 1995||Sep 26, 2000||The Rockfeller University||Nucleic acid primers and probes for the mammalian OB gene|
|US6168956||May 29, 1991||Jan 2, 2001||Beckman Coulter, Inc.||Multiple component chromatographic assay device|
|US6309640||Jun 7, 1995||Oct 30, 2001||The Rockefeller University||Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)|
|US6309853||Jun 7, 1995||Oct 30, 2001||The Rockfeller University||Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof|
|US6350730||Jun 7, 1995||Feb 26, 2002||The Rockefeller University||OB polypeptides and modified forms as modulators of body weight|
|US6419927||Nov 28, 1994||Jul 16, 2002||Anthony Cerami||Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages|
|US6471956||Jun 7, 1995||Oct 29, 2002||The Rockefeller University||Ob polypeptides, modified forms and compositions thereto|
|US6770449||Jan 30, 2001||Aug 3, 2004||Duke University||Methods of assaying receptor activity and constructs useful in such methods|
|US7018812||Nov 5, 2001||Mar 28, 2006||Duke University||Modified G-protein coupled receptors|
|US7163800||Aug 1, 2003||Jan 16, 2007||Molecular Devices Corporation||Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity|
|US7214496||Dec 30, 2004||May 8, 2007||Duke University||Modified G-protein coupled receptors|
|US7541151||Jun 4, 2002||Jun 2, 2009||Duke University||Single-cell biosensor for the measurement of GPCR ligands in a test sample|
|US7553484||Jun 5, 2002||Jun 30, 2009||The Regents Of The University Of California||Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule|
|US7572888||Feb 24, 2004||Aug 11, 2009||Duke University||Methods of assaying receptor activity and constructs useful in such methods|
|US7615610||Jan 26, 2004||Nov 10, 2009||Duke University||Modified trafficking patterns for arrestin and G-protein-coupled receptors via arrestin-ubiquitin chimera|
|US7994301||Aug 9, 2011||The Rockefeller University||Modulators of body weight, corresponding nucleic acids and proteins|
|US8173793||May 6, 2009||May 8, 2012||The Rockefeller University||Nucleic acids encoding modulators of body weight|
|US20030049254 *||Jun 5, 2002||Mar 13, 2003||Kaufman Daniel L.||Modulating neuronal outgrowth via the major histocompatibility complex Class I (MHC I) molecule|
|US20030222908 *||Jun 3, 2002||Dec 4, 2003||Microsoft Corporation||Dynamic wizard interface system and method|
|US20040091946 *||Aug 1, 2003||May 13, 2004||Oakley Robert H.||Methods of screening compositions for G protein -coupled receptor desensitization inhibitory activity|
|US20040186280 *||Dec 18, 2003||Sep 23, 2004||Murdoch University||BmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof|
|US20040209246 *||Apr 5, 2004||Oct 21, 2004||Agouron Pharmaceuticals, Inc.||Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors|
|US20050106623 *||Dec 30, 2004||May 19, 2005||Oakley Robert H.||Modified G-protein coupled receptors|
|US20050136431 *||Jul 29, 2004||Jun 23, 2005||Oakley Robert H.||Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity|
|US20060026702 *||Jul 30, 2004||Feb 2, 2006||Duke University||Phosphoinositide 3-kinase mediated inhibition of GPCRs|
|US20060057151 *||Aug 2, 2005||Mar 16, 2006||Hampson David J||BmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof|
|US20060188944 *||May 9, 2002||Aug 24, 2006||Barak Lawrence S||Methods of assaying receptor activity|
|US20060263828 *||Jan 26, 2004||Nov 23, 2006||Sudha Shenoy||Modified trafficking patterns for arrestin and g-protein-coupled receptors via arrestin-ubiquitin chimera|
|US20080026394 *||Jul 11, 2007||Jan 31, 2008||Antara Biosciences Inc.||Methods of detecting one or more cancer markers|
|US20090324612 *||Jun 24, 2009||Dec 31, 2009||Kaufman Daniel L||Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule|
|EP1810978A2||Aug 8, 2001||Jul 25, 2007||St. Jude Children's Research Hospital||Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof|
|EP1903107A1||Sep 25, 2000||Mar 26, 2008||Cybios LLC||Pluripotent embryonic-like stem cells, compositions, methods and uses thereof|
|EP2224008A2||May 10, 2006||Sep 1, 2010||Murdoch University||Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy|
|EP2308973A1||Oct 20, 1998||Apr 13, 2011||Domantis Limited||Method to screen phage display libraries with different ligands|
|EP2333049A1||Sep 25, 2000||Jun 15, 2011||ABT Holding Company||Pluripotent embryonic-like stem cells, compositions, methods and uses thereof|
|EP2335728A1||May 13, 2002||Jun 22, 2011||Ludwig Institute for Cancer Research Ltd.||Specific binding proteins and uses thereof|
|EP2371955A1||Sep 26, 2003||Oct 5, 2011||K.U. Leuven Research & Development||Integrase cofactor|
|EP2402444A1||Aug 17, 1995||Jan 4, 2012||The Rockefeller University||Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof|
|EP2514763A1||Feb 18, 2005||Oct 24, 2012||The Ludwig Institute for Cancer Research||Egf receptor epitope peptides and uses thereof|
|EP2530087A2||Mar 26, 2009||Dec 5, 2012||Prionics AG||Sequences of brachyspira, immunogenic composition, methods for preparation and use thereof|
|EP2636743A1||Apr 20, 2007||Sep 11, 2013||Intervet International B.V.||Pestivirus species|
|EP2881468A1||Apr 20, 2007||Jun 10, 2015||Intervet International B.V.||Pestivirus species|
|EP2913344A1||Feb 17, 2010||Sep 2, 2015||Ludwig Institute for Cancer Research Ltd||Specific binding proteins and uses thereof|
|EP3018139A2||Aug 3, 2007||May 11, 2016||Boehringer Ingelheim Vetmedica GmbH||Genes and proteins of brachyspira hyodysenteriae and uses thereof|
|WO2009105833A1||Feb 27, 2009||Sep 3, 2009||Murdoch University||Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof|
|WO2009117773A1||Mar 26, 2009||Oct 1, 2009||Murdoch University||Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof|
|WO2010093450A2||Feb 11, 2010||Aug 19, 2010||Ludwing Institute For Cancer Research Ltd.||Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis|
|WO2010096434A2||Feb 17, 2010||Aug 26, 2010||Ludwig Institute For Cancer Research||Specific binding proteins and uses thereof|
|WO2011040972A1||Oct 1, 2010||Apr 7, 2011||Ludwig Institute For Cancer Research Ltd.||Anti-fibroblast activation protein antibodies and methods and uses thereof|
|WO2011040973A2||Oct 1, 2010||Apr 7, 2011||Ludwig Institute For Cancer Research Ltd.||Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof|
|WO2011041319A2||Sep 28, 2010||Apr 7, 2011||Ludwig Institute For Cancer Research||Specific binding proteins and uses thereof|
|WO2012135360A1||Mar 28, 2012||Oct 4, 2012||Ludwig Institute For Cancer Research Ltd.||Binding proteins specific for egfr expressed on tumor and uses thereof|
|U.S. Classification||435/7.8, 435/7.94, 435/810, 436/540, 435/188, 436/501, 435/7.92, 436/542, 435/971, 435/7.95|
|International Classification||G01N33/543, G01N33/541, G01N33/566, G01N33/74|
|Cooperative Classification||G01N33/541, G01N33/54306, G01N33/74, G01N33/566|
|European Classification||G01N33/566, G01N33/541, G01N33/74, G01N33/543B|